Warning on risks: Financial contracts for difference are complex instruments and are associated with a high risk of rapid financial losses due to leverage. On 72.29% of retail investor accounts, financial losses occur when trading financial contracts for difference with this provider. You should consider whether you understand how financial contracts for difference work, and whether you can afford to take the high risk of suffering financial losses. Please read the Risk Disclosures.
Market analysis and news
Get an overview of current market developments with regular analysis from our analysts. We offer a detailed view of key events, economic indicators and investment opportunities. Follow the development of the markets with us and make decisions based on data and experience.
Almost every electronic device we use every day has a microchip embedded in it. Highly specialised machines are needed to manufacture these components and one of the main suppliers is ASML in Veldhoven, the Netherlands. This is one of the most important companies in the production of process equipment for the semiconductor industry. In 2023, this company exceeded analysts' expectations not only in terms of sales but also in terms of profit, and in February 2024 its market value reached USD 372.52 billion.[1][2]
MiCA (Markets in Crypto Assets) regulation is a revolutionary step for European cryptoassets markets, bringing new opportunities and better security to this dynamic and fast-growing sector. For the European Union, it is a ticket to a new era in the digital financial world. This 150-page legal framework builds on similar EU rules for securities trading. Any company wishing to offer cryptocurrency asset services in the EU will have to obtain authorisation from one of the 27 national EU financial regulators.1
Chinese tech giant Baidu will partner with Samsung to integrate the functionality of its chatbot Ernie into Galaxy S24 smartphones in China. This report comes as a big surprise as most of Samsung's smartphones in other countries use technology from the rival company Google, which is under Alphabet's umbrella.
French pharmaceutical company Sanofi has agreed to buy the INBRX-101 drug development project from Inhibrx Inc. It is opening a new account for about $2.2 billion in a bid to boost its rare disease business. The acquisition is in line with the company's portfolio growth strategy and complements Sanofi's 30-year heritage in rare diseases as well as its industry leadership in immunology and inflammation.
Latest analyses